View Financial HealthAlterola Biotech 배당 및 자사주 매입배당 기준 점검 0/6Alterola Biotech 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 30+ 2 more updatesAlterola Biotech, Inc. Announces Resignation of Nathan Thompson as Chief Financial OfficerAlterola Biotech, Inc. announced that On May 16, 2025 Nathan Thompson resigned as Chief Financial Officer.공시 • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2025, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jun 29Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/28/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Oct 18Alterola Biotech, Inc. Announces Executive ChangesAlterola Biotech, Inc. appointed Nathan Thompson as a member of Board of Directors. Nathan Thompson has been Chief Financial Officer of United Science LLC (“United”) since April of 2016, and previously served as Vice President of Operations from April of 2016 to May 2019. Prior to his employment with United, Mr. Thompson served as Corporate Accounting Manager of Link Snacks, Inc. from April 2008 to March 2016. Mr. Thompson also gained audit experience from September 2001 to April 2008 working as a Senior Internal Auditor for ALLETE, Inc. Mr. Thompson brings over 20 years of executive accounting experience to the Board. Mr. Thompson does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940. There are no family relationships between Mr. Thompson and any of directors or executive officers. Mr. Thompson has not had any material direct or indirect interest in any of the Company’s transactions or proposed transactions over the last two years. Also, as a consequence of the expired option for Bright Green Corporation to acquire Alterola and the lack of success of the parties to reach a new agreement, Mr. Terry Rafih, who was appointed in connection with the potential acquisition, is no longer a member of Board of Directors. On October 13, 2023, the company replaced Messrs. Brendan McAleer and Duncan Boxwell with Mr. Hunter Land to serve on the audit committee of company. The committee is now comprised of Ning Qu as Chairperson and Mr. Land, both independent directors of company.공시 • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/15/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jun 30Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.New Risk • Jun 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.07m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$8.07m market cap).공시 • Nov 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Oct 08+ 1 more updateAlterola Biotech, Inc. Executive ChangesOn October 3rd, 2022, Alterola Biotech, Inc. announced Seamus McAuley resigned as Chief Executive Officer, with immediate effect. On October 7, 2022, the board of directors accepted the resignation of Seamus McAuley as Chief Executive Officer. Also on October 7, 2022, the company David Hitchcock was appointed as CEO. David Hitchcock, OBE has worked in the City of London for nearly 30 years, most recently in companies he co-founded to facilitate equity investment into UK Small and Medium Enterprises (SMEs). His experience concentrated particularly in the UK Life Sciences and Precision Engineering Sectors including listings onto the London Stock Exchange. David and his team bought several high precision engineering companies from administration, turning them round and creating over 200 jobs in Wales and the West of England including a standalone apprentice training centre. David spent 21 years in Investment Banking with 10 years as a Managing Director at JPMorgan and Head of Investor Client Management. David and his team managed the bank’s most senior client relationships with its most important institutional asset managers and hedge funds in the UK and EMEA. He began his City career in Equities at Goldman Sachs in 1992. Before entering the City David served as a British Army Officer with The Sixth (Queen Elizabeth’s Own) Gurkha Rifles. He is a Graduate of The Royal Military Academy, Sandhurst and Pembroke College, Cambridge. David has lectured at The Royal College of Defence Studies and the Master of Finance Course at the Judge Business School, Cambridge University. He is a Trustee of several educational and military charities.공시 • Oct 05Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI).Bright Green Corporation (NasdaqCM:BGXX) has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) for $4 million on August 25, 2022. Bright Green will initially purchase 25% of the issued and outstanding common stock of Alterola for total consideration of $4 million and will receive a 6 month option to purchase Alterola’s remaining issued and outstanding common stock for an additional $6 million and approximately $40 million in Bright Green common stock. Terry Rafih, or his designee, shall be appointed to Alterola’s Board of Directors. The transaction is subject to completion of initial satisfactory due diligence, Bright Green shall have obtained and completed sufficient and satisfactory financing of the Purchase Price, other customary conditions and closing of the additional proposed arrangement, which will be set forth in a final definitive agreement. The transaction is expected to close in the second half of 2022. Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) on October 4, 2022.공시 • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Feb 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ABTI 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ABTI 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Alterola Biotech 배당 수익률 vs 시장ABTI의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ABTI)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (ABTI) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ABTI 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ABTI 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ABTI 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ABTI 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 21:22종가2026/02/23 00:00수익2024/09/30연간 수익2024/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Alterola Biotech, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jun 30+ 2 more updatesAlterola Biotech, Inc. Announces Resignation of Nathan Thompson as Chief Financial OfficerAlterola Biotech, Inc. announced that On May 16, 2025 Nathan Thompson resigned as Chief Financial Officer.
공시 • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2025, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jun 29Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/28/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Oct 18Alterola Biotech, Inc. Announces Executive ChangesAlterola Biotech, Inc. appointed Nathan Thompson as a member of Board of Directors. Nathan Thompson has been Chief Financial Officer of United Science LLC (“United”) since April of 2016, and previously served as Vice President of Operations from April of 2016 to May 2019. Prior to his employment with United, Mr. Thompson served as Corporate Accounting Manager of Link Snacks, Inc. from April 2008 to March 2016. Mr. Thompson also gained audit experience from September 2001 to April 2008 working as a Senior Internal Auditor for ALLETE, Inc. Mr. Thompson brings over 20 years of executive accounting experience to the Board. Mr. Thompson does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940. There are no family relationships between Mr. Thompson and any of directors or executive officers. Mr. Thompson has not had any material direct or indirect interest in any of the Company’s transactions or proposed transactions over the last two years. Also, as a consequence of the expired option for Bright Green Corporation to acquire Alterola and the lack of success of the parties to reach a new agreement, Mr. Terry Rafih, who was appointed in connection with the potential acquisition, is no longer a member of Board of Directors. On October 13, 2023, the company replaced Messrs. Brendan McAleer and Duncan Boxwell with Mr. Hunter Land to serve on the audit committee of company. The committee is now comprised of Ning Qu as Chairperson and Mr. Land, both independent directors of company.
공시 • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/15/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jun 30Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
New Risk • Jun 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.07m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$8.07m market cap).
공시 • Nov 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Oct 08+ 1 more updateAlterola Biotech, Inc. Executive ChangesOn October 3rd, 2022, Alterola Biotech, Inc. announced Seamus McAuley resigned as Chief Executive Officer, with immediate effect. On October 7, 2022, the board of directors accepted the resignation of Seamus McAuley as Chief Executive Officer. Also on October 7, 2022, the company David Hitchcock was appointed as CEO. David Hitchcock, OBE has worked in the City of London for nearly 30 years, most recently in companies he co-founded to facilitate equity investment into UK Small and Medium Enterprises (SMEs). His experience concentrated particularly in the UK Life Sciences and Precision Engineering Sectors including listings onto the London Stock Exchange. David and his team bought several high precision engineering companies from administration, turning them round and creating over 200 jobs in Wales and the West of England including a standalone apprentice training centre. David spent 21 years in Investment Banking with 10 years as a Managing Director at JPMorgan and Head of Investor Client Management. David and his team managed the bank’s most senior client relationships with its most important institutional asset managers and hedge funds in the UK and EMEA. He began his City career in Equities at Goldman Sachs in 1992. Before entering the City David served as a British Army Officer with The Sixth (Queen Elizabeth’s Own) Gurkha Rifles. He is a Graduate of The Royal Military Academy, Sandhurst and Pembroke College, Cambridge. David has lectured at The Royal College of Defence Studies and the Master of Finance Course at the Judge Business School, Cambridge University. He is a Trustee of several educational and military charities.
공시 • Oct 05Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI).Bright Green Corporation (NasdaqCM:BGXX) has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) for $4 million on August 25, 2022. Bright Green will initially purchase 25% of the issued and outstanding common stock of Alterola for total consideration of $4 million and will receive a 6 month option to purchase Alterola’s remaining issued and outstanding common stock for an additional $6 million and approximately $40 million in Bright Green common stock. Terry Rafih, or his designee, shall be appointed to Alterola’s Board of Directors. The transaction is subject to completion of initial satisfactory due diligence, Bright Green shall have obtained and completed sufficient and satisfactory financing of the Purchase Price, other customary conditions and closing of the additional proposed arrangement, which will be set forth in a final definitive agreement. The transaction is expected to close in the second half of 2022. Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) on October 4, 2022.
공시 • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Feb 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.